Skip to main content
Erschienen in: Annals of Surgical Oncology 13/2016

28.06.2016 | Gastrointestinal Oncology

Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study

verfasst von: Dario Baratti, MD, Shigeki Kusamura, MD, PhD, Massimo Milione, MD, Filippo Pietrantonio, MD, Marta Caporale, MD, Marcello Guaglio, MD, Marcello Deraco, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Pseudomyxoma peritonei (PMP) usually originates from appendiceal neoplasms and, less commonly, from extra-appendiceal lesions. To date, the clinical and therapeutic implications of extra-appendiceal origin are largely unknown.

Methods

A prospective database of 225 PMP patients uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was reviewed to identify cases with extra-appendiceal primaries. Histologically, negative appendix defined extra-appendiceal origin. Clinical, pathological, and immunohistochemical features (cytokeratin [CK]-20, CK-7, CDX-2, MUC-2, MUC-5A) were correlated with the site of origin. PMP was categorized into low or high grade, according to the 2010 World Health Organization (WHO) classification. The main independent variable for survival analysis was appendiceal versus extra-appendiceal primary.

Results

In 19 patients (8.4 %), PMP origin was the ovary (n = 9), uterine cervix (n = 1), mature cystic teratomas (n = 4), and unknown (n = 5). Appendiceal and extra-appendiceal PMP groups were comparable for all characteristics, except for a prevalence of females in the latter. Median follow-up was 64.1 months (95 % confidence interval [CI] 53.9–80.1), and 10-year overall survival was 63.4 % (median 148.2 months; 95 % CI 131.2–165.2) for appendiceal PMP, and 62.0 % (median not reached) for extra-appendiceal PMP. The difference was not significant at univariate ( p = 0.297) and multivariate analysis (hazard ratio 1.51, 95 % CI 0.78–3.14; p = 0.278). High-grade peritoneal histology (p = 0.007), prior systemic chemotherapy (p = 0.003), more than four visceral resections (p = 0.011), and incomplete cytoreduction (p = 0.021) independently correlated with poorer survival.

Conclusions

Clinical-pathological features of PMP, and outcome after CRS/HIPEC, did not differ according to the primary site, thus suggesting that PMP is a relatively homogeneous disease that can be produced by a range of histopathologic entities. Extra-appendiceal origin does not contraindicate CRS/HIPEC.
Literatur
1.
Zurück zum Zitat Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.CrossRefPubMed Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.CrossRefPubMed
2.
Zurück zum Zitat Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol. 2005;12:291–311.CrossRefPubMed Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol. 2005;12:291–311.CrossRefPubMed
3.
Zurück zum Zitat Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134:864–70.PubMed Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134:864–70.PubMed
4.
Zurück zum Zitat Panarelli NC, Yantiss RK. Mucinous neoplasms of the appendix and peritoneum. Arch Pathol Lab Med. 2011;135:1261–8.CrossRefPubMed Panarelli NC, Yantiss RK. Mucinous neoplasms of the appendix and peritoneum. Arch Pathol Lab Med. 2011;135:1261–8.CrossRefPubMed
5.
Zurück zum Zitat Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg. 2013;79:1171–76.PubMed Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg. 2013;79:1171–76.PubMed
6.
Zurück zum Zitat Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014;27:1521–39.CrossRefPubMed Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014;27:1521–39.CrossRefPubMed
8.
Zurück zum Zitat Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112–9.CrossRefPubMedPubMedCentral Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112–9.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089–103.CrossRefPubMed Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089–103.CrossRefPubMed
10.
Zurück zum Zitat Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–8.CrossRefPubMedPubMedCentral Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–8.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Järvinen P, Järvinen HJ, Lepistö A. Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis. 2010;12:868–72.CrossRefPubMed Järvinen P, Järvinen HJ, Lepistö A. Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis. 2010;12:868–72.CrossRefPubMed
12.
Zurück zum Zitat Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.CrossRefPubMed Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.CrossRefPubMed
13.
Zurück zum Zitat González-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91:304–11.CrossRefPubMed González-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91:304–11.CrossRefPubMed
14.
Zurück zum Zitat Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–9.CrossRefPubMed Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–9.CrossRefPubMed
15.
Zurück zum Zitat Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic chemotherapy. Ann Surg. 2007;245:104–9.CrossRefPubMedPubMedCentral Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic chemotherapy. Ann Surg. 2007;245:104–9.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Elias D, Honoré C, Ciuchendéa R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95:1164–71.CrossRefPubMed Elias D, Honoré C, Ciuchendéa R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95:1164–71.CrossRefPubMed
17.
Zurück zum Zitat Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243–9.CrossRefPubMed Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243–9.CrossRefPubMed
18.
Zurück zum Zitat Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456–62.CrossRefPubMed Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456–62.CrossRefPubMed
19.
Zurück zum Zitat Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMed Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMed
20.
Zurück zum Zitat Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis. 2015;17:772–8.CrossRefPubMed Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis. 2015;17:772–8.CrossRefPubMed
21.
Zurück zum Zitat Milovanov V, Sardi A, Studeman K, Nieroda C, Sittig M, Gushchin V. The 7th edition of the AJCC staging classification correlates with biologic behavior of mucinous appendiceal tumor with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Ann Surg Oncol. 2016;23(6):1928–33.CrossRefPubMed Milovanov V, Sardi A, Studeman K, Nieroda C, Sittig M, Gushchin V. The 7th edition of the AJCC staging classification correlates with biologic behavior of mucinous appendiceal tumor with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Ann Surg Oncol. 2016;23(6):1928–33.CrossRefPubMed
22.
Zurück zum Zitat Wagner PL, Austin F, Zenati M, et al. Oncologic risk stratification following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal carcinomatosis. Ann Surg Oncol. 2016;23(5):1587–93.CrossRefPubMed Wagner PL, Austin F, Zenati M, et al. Oncologic risk stratification following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal carcinomatosis. Ann Surg Oncol. 2016;23(5):1587–93.CrossRefPubMed
23.
Zurück zum Zitat Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19:1390–408.CrossRefPubMed Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19:1390–408.CrossRefPubMed
24.
Zurück zum Zitat Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol. 1999;154:1849–55.CrossRefPubMedPubMedCentral Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol. 1999;154:1849–55.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis and expression of p53, CD44, bcl-2. Arch Pathol Lab Med. 2002;126:837–41.PubMed Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis and expression of p53, CD44, bcl-2. Arch Pathol Lab Med. 2002;126:837–41.PubMed
26.
Zurück zum Zitat Nonaka D, Kusamura S, Baratti D, et al. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology. 2006;49:381–7.CrossRefPubMed Nonaka D, Kusamura S, Baratti D, et al. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology. 2006;49:381–7.CrossRefPubMed
27.
Zurück zum Zitat Ikejiri K, Anai H, Kitamura K, et al. Pseudomyxoma peritonei concomitant with early gastric cancer: report of a case. Surg Today. 1996;26:923–5.CrossRefPubMed Ikejiri K, Anai H, Kitamura K, et al. Pseudomyxoma peritonei concomitant with early gastric cancer: report of a case. Surg Today. 1996;26:923–5.CrossRefPubMed
28.
Zurück zum Zitat de Bree E, Witkamp A, Van De Vijver M, Zoetmulde F. Unusual origins of pseudomyxoma peritonei. J Surg Oncol. 2000;75:270–4.CrossRefPubMed de Bree E, Witkamp A, Van De Vijver M, Zoetmulde F. Unusual origins of pseudomyxoma peritonei. J Surg Oncol. 2000;75:270–4.CrossRefPubMed
29.
Zurück zum Zitat Chejfec G, Rieker WJ, Jablokow VR, et al. Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology. 1986;90:202–5.CrossRefPubMed Chejfec G, Rieker WJ, Jablokow VR, et al. Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology. 1986;90:202–5.CrossRefPubMed
30.
Zurück zum Zitat Liu Y, Ishibashi H, Hirano M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei arising from urachus. Ann Surg Oncol. 2015;22(8):2799–805.CrossRefPubMed Liu Y, Ishibashi H, Hirano M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei arising from urachus. Ann Surg Oncol. 2015;22(8):2799–805.CrossRefPubMed
31.
Zurück zum Zitat Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol. 2003;27:650–7.CrossRefPubMed Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol. 2003;27:650–7.CrossRefPubMed
32.
Zurück zum Zitat Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 2012 65: 919–23.CrossRefPubMed Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 2012 65: 919–23.CrossRefPubMed
33.
Zurück zum Zitat Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58. Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.
34.
Zurück zum Zitat Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.CrossRefPubMed Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.CrossRefPubMed
35.
Zurück zum Zitat Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO classification of tumors of the digestive system. Lyon: IARC; 2010. pp. 122–5. Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO classification of tumors of the digestive system. Lyon: IARC; 2010. pp. 122–5.
36.
Zurück zum Zitat Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016:40(1):14–26.CrossRefPubMed Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016:40(1):14–26.CrossRefPubMed
37.
Metadaten
Titel
Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study
verfasst von
Dario Baratti, MD
Shigeki Kusamura, MD, PhD
Massimo Milione, MD
Filippo Pietrantonio, MD
Marta Caporale, MD
Marcello Guaglio, MD
Marcello Deraco, MD
Publikationsdatum
28.06.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 13/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5350-9

Weitere Artikel der Ausgabe 13/2016

Annals of Surgical Oncology 13/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.